{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Najahi-Missaoui W"],"funding":["U.S. Department of Defense","National Institutes of Health","National Institute of Biomedical Imaging and Bioengineering"],"pagination":["e00518"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6728842"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(5)"],"pubmed_abstract":["P21-activated kinase-1 (PAK-1) is a serine/threonine kinase involved in multiple signaling pathways that mediate cellular functions such as cytoskeletal motility, cell proliferation, and survival. PAK-1 expression is altered in various cancers, including prostate and breast. Our recent studies showed that prostate cancer cells expressing higher levels of PAK-1 were resistant to the cytotoxic effects of the PAK-1 inhibitor, inhibitor targeting PAK-1 activation-3 (IPA-3), compared to those with lower expression. This study expanded these findings to other cancers (breast and melanoma) by testing the hypothesis that genetic and pharmacological inhibition of PAK-1 alters cell growth, migration, and invasion in prostate, breast, and skin cancer cell lines. We also tested the specificity of IPA-"],"journal":["Pharmacology research & perspectives"],"pubmed_title":["Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion."],"pmcid":["PMC6728842"],"funding_grant_id":["11996600","EB0160100"],"pubmed_authors":["Somanath PR","Quach ND","Jenkins A","Dabke I","Cummings BS","Najahi-Missaoui W"],"additional_accession":[]},"is_claimable":false,"name":"Effect of P21-activated kinase 1 (PAK-1) inhibition on cancer cell growth, migration, and invasion.","description":"P21-activated kinase-1 (PAK-1) is a serine/threonine kinase involved in multiple signaling pathways that mediate cellular functions such as cytoskeletal motility, cell proliferation, and survival. PAK-1 expression is altered in various cancers, including prostate and breast. Our recent studies showed that prostate cancer cells expressing higher levels of PAK-1 were resistant to the cytotoxic effects of the PAK-1 inhibitor, inhibitor targeting PAK-1 activation-3 (IPA-3), compared to those with lower expression. This study expanded these findings to other cancers (breast and melanoma) by testing the hypothesis that genetic and pharmacological inhibition of PAK-1 alters cell growth, migration, and invasion in prostate, breast, and skin cancer cell lines. We also tested the specificity of IPA-","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Oct","modification":"2025-04-04T21:30:32.554Z","creation":"2019-09-24T07:08:06Z"},"accession":"S-EPMC6728842","cross_references":{"pubmed":["31516713"],"doi":["10.1002/prp2.518"]}}